Two Original Chinese Stroke Studies Published Simultaneously in NEJM | UnionStrong® Pushes the Boundaries of Stroke Care with AI

On the morning of October 24, 2026 (Beijing Time), at the opening ceremony of OCIN 2026, two clinical stroke studies, MILD-MT and LATE-MT, led by Professors Liu Jianmin and Yang Pengfei from the First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital) in collaboration with multiple stroke centers across China, were simultaneously published online in the New England Journal of Medicine (NEJM). Qin Lan, Founder, Chairman, and General Manager of UnionStrong®, was invited to join distinguished leaders and experts on stage for the official unveiling of the research findings.

With the publication of these two studies in NEJM, UnionStrong®'s independently developed UGuard® has become the world's only AI decision-support tool backed by evidence from an international clinical study on mechanical thrombectomy in the extended 24–72-hour treatment window.

The two studies focused on distinct patient populations: patients with mild stroke caused by large vessel occlusion within 24 hours of symptom onset, and patients presenting 24–72 hours after stroke onset, beyond the conventional thrombectomy treatment window. Together, they provide high-quality clinical evidence to support the exploration of new opportunities for thrombectomy treatment.

For UnionStrong®, this milestone represents not only a major achievement in clinical research involving its proprietary technology, but also demonstrates how homegrown Chinese AI innovations are helping clinicians address critical questions in stroke care: Which patients may still benefit from treatment? How can patients who were previously difficult to assess—or considered beyond the treatment window—be given another opportunity for evaluation and potentially life-saving intervention?